Literature DB >> 23293754

Multiple roles of angiotensin in colorectal cancer.

Hiroki Kuniyasu1.   

Abstract

Colorectal cancer (CRC) cells express renin and chymase through which they can activate angiotensin. Renin expression is induced by hyperglycemic conditions. As angiotensinogen is produced in the liver, CRC cells that can activate angiotensin have an enhanced ability to metastasize to this organ. In human CRC cases, patients with diabetes have higher activities of rennin and angiotensin-II in primary tumors, and on average, have a more progressed disease stage, especially with respect to liver metastasis. These patients exhibit a stronger association with Hemoglobin A1c levels and metastasis compared to patients without diabetes. In a combined diabetes/CRC liver metastasis mouse model, concurrent treatment with anti-angiotensin and hypoglycemic agents shows a synergic effect in terms of reduced liver metastasis and improved survival. The effect of anti-angiotensin treatment and blood sugar control as a baseline management for colon cancer patients with diabetes needs to be examined in clinical trials to establish whether it can prevent liver metastasis.

Entities:  

Keywords:  Angiotensin; Angiotensin II receptor blocker; Diabetes; Liver metastasis; Renin

Year:  2012        PMID: 23293754      PMCID: PMC3536833          DOI: 10.5306/wjco.v3.i12.150

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


  35 in total

1.  Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro.

Authors:  M Ogasawara; J Murata; K Ayukawa; I Saimi
Journal:  Cancer Lett       Date:  1997-06-03       Impact factor: 8.679

Review 2.  Carcinogenicity of antihypertensive therapy.

Authors:  Ehud Grossman; Franz H Messerli; Uri Goldbourt
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 3.  Angiotensin I converting enzyme and chymase in cardiovascular tissues.

Authors:  H Nishimura; S Hoffmann; O Baltatu; K Sugimura; D Ganten; H Urata
Journal:  Kidney Int Suppl       Date:  1996-06       Impact factor: 10.545

Review 4.  Epidemiological aspects of neoplasms in diabetes.

Authors:  Antonio Nicolucci
Journal:  Acta Diabetol       Date:  2010-04-08       Impact factor: 4.280

5.  Diabetes-associated angiotensin activation enhances liver metastasis of colon cancer.

Authors:  Takasumi Shimomoto; Hitoshi Ohmori; Yi Luo; Yoshitomo Chihara; Ayumi Denda; Tomonori Sasahira; Naokuni Tatsumoto; Kiyomu Fujii; Hiroki Kuniyasu
Journal:  Clin Exp Metastasis       Date:  2012-05-03       Impact factor: 5.150

Review 6.  Angiotensin II-generating enzymes.

Authors:  L A Belova
Journal:  Biochemistry (Mosc)       Date:  2000-12       Impact factor: 2.487

Review 7.  Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer.

Authors:  Elizabeth Escobar; Tatiana Sofía Rodríguez-Reyna; Oscar Arrieta; Julio Sotelo
Journal:  Curr Vasc Pharmacol       Date:  2004-10       Impact factor: 2.719

Review 8.  Treatment of colorectal cancer: hepatic metastasis.

Authors:  Y Fong; N Kemeny; P Paty; L H Blumgart; A M Cohen
Journal:  Semin Surg Oncol       Date:  1996 Jul-Aug

Review 9.  Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies.

Authors:  Randal A Skidgel; Ervin G Erdös
Journal:  Peptides       Date:  2004-03       Impact factor: 3.750

10.  Phenotypic expression of gastrointestinal differentiation markers in colorectal adenocarcinomas with liver metastasis.

Authors:  Takashi Yao; Miyuki Takata; Shuichi Tustsumi; Ken-ichi Nishiyama; Ken-ichi Taguchi; Eishi Nagai; Masazumi Tsuneyoshi
Journal:  Pathology       Date:  2002-12       Impact factor: 5.306

View more
  7 in total

Review 1.  Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.

Authors:  Patrycja Nowak-Sliwinska; Leonardo Scapozza; Ariel Ruiz i Altaba
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-04-26       Impact factor: 10.680

2.  Expression of MAS1 in breast cancer.

Authors:  Yi Luo; Eriko Tanabe; Misaho Kitayoshi; Yukiko Nishiguchi; Rina Fujiwara; Sayako Matsushima; Takamitsu Sasaki; Tomonori Sasahira; Yoshitomo Chihara; Dai Nakae; Kiyomu Fujii; Hitoshi Ohmori; Hiroki Kuniyasu
Journal:  Cancer Sci       Date:  2015-07-20       Impact factor: 6.716

Review 3.  EXPRESSION OF THE RENIN-ANGIOTENSIN SYSTEM COMPONENTS IN ONCOLOGIC DISEASES.

Authors:  Sergey Dolomatov; Walery Zukow; Nikolay Novikov; Alexandra Markaryan; Elena Eremeeva
Journal:  Acta Clin Croat       Date:  2019-06       Impact factor: 0.780

4.  Raynaud's Phenomenon: Beware of Cancers!

Authors:  Zahida Aqodad; Houda Bachir; Habiba Alaoui; Siham Hamaz; Khalid Serraj
Journal:  Cureus       Date:  2021-03-20

5.  Risk factors for long-term survival in patients with ypN+ M0 rectal cancer after radical anterior resection.

Authors:  Marcin Zeman; Władysław Skałba; Piotr Szymański; Grzegorz Hadasik; Dmytro Żaworonkow; Dominik A Walczak; Agnieszka Czarniecka
Journal:  BMC Gastroenterol       Date:  2022-03-26       Impact factor: 3.067

6.  Adenomatous polyposis coli in cancer and therapeutic implications.

Authors:  Olivia Noe; Louis Filipiak; Rachel Royfman; Austin Campbell; Leslie Lin; Danae Hamouda; Laura Stanbery; John Nemunaitis
Journal:  Oncol Rev       Date:  2021-06-24

7.  Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.

Authors:  M R Jones; K A Schrader; Y Shen; E Pleasance; C Ch'ng; N Dar; S Yip; D J Renouf; J E Schein; A J Mungall; Y Zhao; R Moore; Y Ma; B S Sheffield; T Ng; S J M Jones; M A Marra; J Laskin; H J Lim
Journal:  Ann Oncol       Date:  2016-02-18       Impact factor: 32.976

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.